Compass Therapeutics (NASDAQ:CMPX) Cut to “Sell” at Wall Street Zen

Compass Therapeutics (NASDAQ:CMPX) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Sunday.

Other equities research analysts have also issued reports about the company. Citigroup began coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They set an “outperform” rating for the company. William Blair began coverage on Compass Therapeutics in a research note on Monday, January 5th. They set an “outperform” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Wednesday, January 21st. Canaccord Genuity Group set a $13.00 target price on shares of Compass Therapeutics in a report on Wednesday. Finally, JMP Securities set a $10.00 target price on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $12.46.

Compass Therapeutics Price Performance

Compass Therapeutics stock opened at $6.52 on Friday. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -14.49 and a beta of 1.46. The firm has a 50-day moving average of $5.56 and a two-hundred day moving average of $4.38. Compass Therapeutics has a 1 year low of $1.33 and a 1 year high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.06. Research analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. lifted its position in Compass Therapeutics by 3,933.7% during the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after acquiring an additional 7,592 shares during the last quarter. Creative Planning purchased a new position in Compass Therapeutics in the second quarter worth $30,000. Flagship Harbor Advisors LLC acquired a new position in shares of Compass Therapeutics during the fourth quarter worth $32,000. Strs Ohio acquired a new position in shares of Compass Therapeutics during the first quarter worth $34,000. Finally, Apollon Wealth Management LLC purchased a new stake in shares of Compass Therapeutics during the 3rd quarter valued at $35,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.